Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Double-blind Treatment	STARTED	Lenalidomide	90
Double-blind Treatment	STARTED	Placebo to Lenalidomide	94
Double-blind Treatment	Safety and ITT Population	Lenalidomide	87
Double-blind Treatment	Safety and ITT Population	Placebo to Lenalidomide	93
Double-blind Treatment	COMPLETED	Lenalidomide	68
Double-blind Treatment	COMPLETED	Placebo to Lenalidomide	79
Double-blind Treatment	NOT COMPLETED	Lenalidomide	22
Double-blind Treatment	NOT COMPLETED	Placebo to Lenalidomide	15
Open-label Extension	STARTED	Lenalidomide	64
Open-label Extension	STARTED	Placebo to Lenalidomide	78
Open-label Extension	COMPLETED	Lenalidomide	19
Open-label Extension	COMPLETED	Placebo to Lenalidomide	29
Open-label Extension	NOT COMPLETED	Lenalidomide	45
Open-label Extension	NOT COMPLETED	Placebo to Lenalidomide	49

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00109772/flow